Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"Minimal Residual Disease Testing for Diffuse Large B Cell Lymphoma.","authors":"Miral Atout, Hadeel Elwaheidi, Rand Maarouf, Abdulwahab A Albabtain, Saud Alhayli, Alfadel Alshaibani, Mahmoud Aljurf, Riad El Fakih","doi":"10.1016/j.clml.2025.05.003","DOIUrl":"https://doi.org/10.1016/j.clml.2025.05.003","url":null,"abstract":"<p><strong>Purpose of review: </strong>Diffuse Large B-cell Lymphoma (DLBCL) is challenging to treat in the context of relapsed and refractory disease. Although approximately 65% of patients are cured with frontline chemotherapy, 35% remain refractory or subsequently relapse following frontline therapy, indicating an urgent need for tailored therapies. This review presents how Minimal Residual Disease (MRD) testing, specifically through the analysis of circulating tumor DNA (ctDNA) in blood, serves as a clinical prognostic factor that may predict relapses and aid in treatment decisions.</p><p><strong>Recent findings: </strong>We describe multiple MRD detection techniques, including droplet digital polymerase chain reaction (DdPCR) and next-generation sequencing (NGS), emphasizing their importance in understanding patients' responses to treatment and in assessing risk levels.</p><p><strong>Summary: </strong>The analysis of ctDNA could be a promising tool to guide physicians to intervene earlier, possibly improving patient outcomes and quality of life. Nonetheless, standardizing these detection techniques and integrating them into clinical practice remain challenging. Future research is crucial to address these barriers, paving the path for greater use of MRD testing in DLBCL management and improving the delivery of effective treatment to patients.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma.","authors":"Sarit E Assouline, Amitkumar Mehta, Walter Hanel, Stéphane Doucet, Patrick B Johnston, AlexeyV Danilov, Brenda W Cooper, Aleksander Chudnovsky, Junyu Ding, Tao Long, Dina Stroopinsky, Deborah Berg, Lapo Alinari","doi":"10.1016/j.clml.2025.04.020","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.020","url":null,"abstract":"<p><strong>Background: </strong>Subasumstat (TAK-981) is an investigational, first-in-class, innate immunity enhancer that unlocks innate/adaptive immune responses in target tumor microenvironments through SUMOylation inhibition. Subasumstat enhanced antitumor activity of rituximab in preclinical xenograft models.</p><p><strong>Patients and methods: </strong>This phase I/II study enrolled 34 patients (n = 31, phase I; n = 3, phase II) with CD20+-positive relapsed/refractory non-Hodgkin lymphoma (NHL); patients with indolent NHL had to be refractory to an anti-CD20 antibody. In phase I, patients received intravenous subasumstat (10-120 mg) once weekly (QW) (or twice weekly [BIW], 90 mg only) with intravenous rituximab 375 mg/m².</p><p><strong>Results: </strong>No dose-limiting toxicities were reported, no maximum tolerated dose was identified up to 120 mg QW. Safety outcomes were comparable across QW dosing cohorts; grade ≥ 3 and serious adverse events (AEs) were more common in the BIW cohort. The most common AEs reported during dose escalation were pyrexia (55%), chills (39%), and fatigue (35%). Most AEs were transient and consistent with low-grade flu-like symptoms, indicative of interferon pathway activation. Overall, 8/29 evaluable patients receiving QW dosing achieved an objective response (2 complete responses; 6 partial responses); the overall best response rate was 27.6%. Pharmacodynamic analyses provided evidence of dose-dependent target engagement (subasumstat-SUMO adduct and SUMOylation pathway inhibition) in blood and skin. Induction of a type-I interferon response, demonstrated by gene expression analysis, increased plasma cytokines/chemokine levels, and activation of innate and adaptative immune response was also observed.</p><p><strong>Conclusion: </strong>This study demonstrated a positive benefit-risk profile of subasumstat combined with rituximab in NHL.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | High-Grade B-Cell Lymphomas: Pathologic and Molecular Classification and Therapeutic Implications.","authors":"Rafaella Litvin, Agrima Mian, Sarah L Ondrejka, Brian T Hill","doi":"10.1016/j.clml.2025.04.021","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.021","url":null,"abstract":"<p><p>High-grade B-cell lymphomas (HGBLs) represent a diverse and aggressive group of neoplasms that lie at the intersection of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), characterized by unique molecular and clinical features. The recently published International Consensus Classification of Myeloid and Lymphoid Neoplasms (ICC) and the fifth edition WHO Classification of Hematolymphoid Tumors have refined the classification of HGBLs dividing them into subtypes based on clinical, morphologic, and molecular features, with subtle differences in terminology and entity characterization. These lymphomas present significant diagnostic challenges due to overlapping features with DLBCL and BL, and their aggressive clinical course necessitates tailored treatment strategies. Conventional therapies, such as R-CHOP, have demonstrated limited efficacy in these patients, prompting exploration of more intensive regimens and targeted therapies. The identification of molecular biomarkers, such as MYC, BCL2, and/or BCL6 rearrangements, as well as the emerging molecular high-grade (MHG) signature, holds promise for better understanding the pathogenesis of these lymphomas and improving prognostic stratification. Despite advances in classification, no clear consensus exists on optimal treatment approaches, and outcomes remain suboptimal, particularly in cases with isolated MYC translocations. This review aims to summarize the current pathologic and molecular classification of HGBLs, highlight the diagnostic challenges, and explore therapeutic implications, including potential future directions for treatment strategies and molecular-targeted therapies.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia.","authors":"Rupal O'Quinn, Anthony J Corry, Naghmana Bajwa, Suman Jannuru, Hong Chen, Paulo Miranda, Jennifer R Brown","doi":"10.1016/j.clml.2025.04.018","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.018","url":null,"abstract":"<p><strong>Background: </strong>The first-generation Bruton tyrosine kinase (BTK) inhibitor ibrutinib is effective in patients with CLL but is associated with considerable cardiac toxicity. The more selective second-generation BTK inhibitor acalabrutinib has demonstrated a more favorable cardiovascular safety profile with fewer atrial fibrillation events versus ibrutinib. We performed a comprehensive analysis of cardiac outcomes with acalabrutinib versus active comparators, including ibrutinib, in patients with and without baseline cardiovascular disorders.</p><p><strong>Materials and methods: </strong>Data from three phase 3 trials in CLL (ELEVATE-RR, ELEVATE-TN, ASCEND) were used. Exposure-adjusted incidence rates (EAIR; events/100 person-months) were reported for system organ class \"cardiac disorders\" in patients overall and by number of baseline cardiovascular disorders. All analyses were descriptive. No statistical comparisons were performed.</p><p><strong>Results: </strong>In total, 1362 patients were included; 404 (29.7%) had ≥1 baseline cardiovascular disorder. The overall EAIR of any-grade cardiac disorder events was lower for acalabrutinib versus active comparator in each trial, and acalabrutinib did not increase cardiac events in patients with ≥1 baseline cardiovascular disorder. The EAIR of de novo cardiac disorder events (ie, among patients without baseline cardiovascular disorders) was also lower for acalabrutinib versus active comparator across trials (ELEVATE-RR: 0.34 vs. 0.67 [acalabrutinib vs. ibrutinib], ELEVATE-TN: 0.28 and 0.25 vs. 0.59 [acalabrutinib plus obinutuzumab and acalabrutinib vs. chlorambucil + obinutuzumab], ASCEND: 0.28 vs. 0.44 and 0.54 [acalabrutinib vs. idelalisib plus rituximab and bendamustine plus rituximab]).</p><p><strong>Conclusions: </strong>The EAIRs of cardiac disorder events was relatively low overall with acalabrutinib versus comparators, regardless of the presence of baseline cardiovascular disorders.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Sponsors on Development of Clinical Research in Multiple Myeloma and AL Amyloidosis: An In-Depth Analysis","authors":"Anas Zayad ,&nbsp;Nausheen Ahmed ,&nbsp;Zahra Mahmoudjafari ,&nbsp;Barry S Skikne ,&nbsp;Tara Lin ,&nbsp;Muhammad U Mushtaq ,&nbsp;Joseph McGuirk ,&nbsp;Forat Lutfi ,&nbsp;Evguenia Bhurtel ,&nbsp;Manisha Bhutani ,&nbsp;Faiz Anwar ,&nbsp;Omar Alkharabsheh ,&nbsp;Atrash Shebli ,&nbsp;Al-Ola Abdallah","doi":"10.1016/j.clml.2025.04.019","DOIUrl":"10.1016/j.clml.2025.04.019","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 8","pages":"Pages e600-e603"},"PeriodicalIF":2.7,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of Cardiovascular Events and Carotid Artery USG Abnormalities in Chronic Myeloid Leukemia Patients on Nilotinib Therapy: A 20-Year Single-Center Study.","authors":"Youngeun Jang, Joon Ho Moon, Yunji Lee, Jung Min Lee, Dong Won Baek, Soon Hee Chang, Sang Kyun Sohn","doi":"10.1016/j.clml.2025.04.015","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.015","url":null,"abstract":"<p><strong>Background: </strong>The incidence of cardiovascular events (CVEs) among patients receiving nilotinib is a critical concern, particularly for those on long-term use. This study aimed to evaluate the incidence of CVEs among chronic myeloid leukemia (CML) patients and assess the efficacy of carotid artery ultrasonography (USG) in predicting CVEs in nilotinib-treated patients.</p><p><strong>Methods: </strong>We retrospectively reviewed 218 patients diagnosed with CML chronic phase who received nilotinib at the Kyungpook National University Hospital, South Korea, from January 2000 to May 2024. Carotid USG was performed on 51 patients. CVEs were defined as acute coronary syndrome, ischemic stroke, and peripheral arterial occlusive disease.</p><p><strong>Results: </strong>Among 218 patients, 41 (18.81%) experienced CVEs, with incidence increasing throughout nilotinib exposure - 15.0% at 5 years, 32.6% at 10 years, and 39.9% at 15 years. Cardiovascular risk factors, including hypertension, diabetes mellitus, dyslipidemia, influenced the occurrence of CVEs (P = .016). The 10-year cumulative CVE incidence in the patient group with ≥2 risk factors was 64.0% after nilotinib treatment. Carotid artery USG was performed in 51 out of 218 patients taking nilotinib. The correlation between cardiovascular risk factors and USG abnormalities was not statistically significant (P = 1.00).</p><p><strong>Conclusions: </strong>Nilotinib treatment in CML patients is associated with significant CVE incidence, which increases with treatment duration and the number of risk factors. Our findings support routine cardiovascular monitoring, particularly carotid USG, within the first year and regular follow-ups every 1 to 2 years based on risk factors. Proactive monitoring, risk-adjusted follow-up, and treatment-free remission considerations could help mitigate CVE risks.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | Transplant in Adult Acute Lymphoblastic Leukemia.","authors":"Curtis Marcoux, Partow Kebriaei","doi":"10.1016/j.clml.2025.04.016","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.016","url":null,"abstract":"<p><p>The landscape of acute lymphoblastic leukemia (ALL) treatment is rapidly evolving, with new therapies challenging traditional treatment paradigms. While allogeneic hematopoietic cell transplantation (allo-HCT) remains essential for many high-risk patients, advances in measurable residual disease (MRD) monitoring and the increasing use of immunotherapies in earlier treatment lines have reshaped transplant decision-making. Improvements in donor availability, conditioning strategies, and post-transplant care have expanded access and improved survival, yet relapse and toxicity remain major challenges. This review examines the evolving role of allo-HCT in ALL, highlighting key advancements and ongoing challenges.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims.","authors":"Rami S Komrokji, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, Tim Werwath, Zhuoer Xie, Eric Padron, David A Sallman","doi":"10.1016/j.clml.2025.04.014","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.014","url":null,"abstract":"<p><strong>Background: </strong>Most patients with lower-risk myelodysplastic syndromes (LR-MDS) develop red blood cell transfusion dependence (RBC-TD). RBC-TD has been associated with decreased quality of life and overall survival (OS).</p><p><strong>Methods: </strong>This study assessed association between RBC-TD and survival using International Classification of Diseases, Tenth Revision (ICD.10), codes and patterns of MDS medication from a large US health insurance claims database (October 2015-March 2023) in 6531 patients who received ≥1 line of treatment.</p><p><strong>Results: </strong>Erythropoiesis-stimulating agent and hypomethylating agent monotherapy were treatments most commonly used in first-line (1L) and second-line (2L) settings. At baseline, 8% of patients had high transfusion burden (≥8 RBC U/8 weeks). In 1L and 2L, ≥16-week RBC transfusion independence (TI) was achieved by 41% (n = 935/2301) and 32% (n = 239/745) of patients, respectively. Median real-world progression-free survival (rwPFS; time from start of treatment to next treatment or progression/death, whichever occurred first) and median OS (mOS) were significantly longer in ≥16-week RBC-TI responders than nonresponders. Median (95% confidence interval [CI]) rwPFS in 1L responders versus nonresponders was 18.0 months (17.0-19.3) versus 3.3 months (3.0-3.5; P < .0001), respectively, and was 20.5 months (17.6-23.7) versus 4.1 months (3.7-4.6; P < .0001), respectively, in 2L. mOS (95% CI) in 1L responders versus nonresponders was 28.7 months (26.1-31.6) versus 8.0 months (7.0-9.1; P < .0001), respectively, and 45.2 months (35.9-49.8) versus 9.0 months (7.6-10.6; P < .0001), respectively, in 2L. RBC-TI achievement was associated with improved survival.</p><p><strong>Conclusions: </strong>Results suggest RBC-TD may be a modifiable factor corresponding to clinical outcomes in LR-MDS, further supporting RBC-TI as a primary endpoint in clinical studies.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Malignant Progression to Adult-T-Cell Leukemia/Lymphoma in HTLV-1 Carriers: A Systematic Review of Cohort and Case-Control Studies.","authors":"Jose M Estrada-Grossmann, Esteban A Alarcón-Braga, Farley E Salazar-Valdivia, Abigail S Jauregui-Cornejo, Karlos Acurio, Niels Pacheco-Barrios, Ali Al-Kassab-Córdova, Daniel Enriquez-Vera","doi":"10.1016/j.clml.2025.04.013","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.013","url":null,"abstract":"<p><strong>Objective: </strong>To systematically evaluate and synthesize the existing evidence from cohort and case-control studies to identify risk factors associated with malignant progression to ATLL in HTLV-1 carriers.</p><p><strong>Methods: </strong>A systematic search was conducted in September 2023 in the following databases: Pubmed, Scopus, Web of Science, Medline and Embase. Only case-control and cohort studies that assessed the risk factors for the malignant progression to ATLL among HTLV-1 carriers in the adult population were included. The risk of bias was assessed through the Newcastle-Ottawa Scale. Meta-analysis was not performed due to high statistical and methodological heterogeneity.</p><p><strong>Results: </strong>After conducting a systematic search, 8170 results were retrieved, of which 9 (7 case-control and 2 cohort studies) met the selection criteria. Seven of them were conducted in Japan and six had low risk of bias. Serum sIL-2R levels, proviral load (PVL), cigarette consumption, Scd30 and TNF-α-857T allele were associated with an increased risk of ATLL progression.</p><p><strong>Conclusion: </strong>PVL emerges as the foremost recommended biomarker for predicting progression in patients with HTLV-1 associated ATLL. Further studies with larger samples sizes, different populations, more rigorous statistical adjustments, and longer follow-up are warranted.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of a Multidisciplinary Program (Amyloidosis Program of Calgary) on Recognition and Intervention for AL and ATTR Amyloidosis.","authors":"Aksha Burande, Nowell Fine, Robert Jh Miller, Christopher Hahn, Etienne Mahe, Debra Bosley, Lyndsay Litwin, Victor H Jimenez-Zepeda","doi":"10.1016/j.clml.2025.04.009","DOIUrl":"https://doi.org/10.1016/j.clml.2025.04.009","url":null,"abstract":"<p><strong>Background: </strong>The diagnosis and management of amyloidosis requires strong coordination among various teams and a multidisciplinary approach which is essential for providing the diagnostic tools needed for patients with organ amyloid deposition.</p><p><strong>Methods: </strong>In this study, we reviewed the referral patterns to the cardiac and hematology amyloid clinics since the inception of the Amyloidosis Program of Calgary (APC) in 2019. The APC was established to facilitate the diagnosis and treatment of amyloidosis. Additionally, a central referral system was created to expedite the triage of cases with potential amyloid-related symptoms.</p><p><strong>Results: </strong>The cardiac amyloid clinic saw an increase in referrals from 41 in 2018 to 105 in 2022, although there was a temporary decrease from 67 in 2019 to 56 in 2020 during the first year of the pandemic. Most referrals came from nonamyloid cardiology clinics, followed by hematology referrals. Fifty percent of the cases referred were patients with ATTR and 18% represented AL cases. Moreover, amyloid clinic at our cancer center also began receiving referrals via the central triage system in 2019, with AL amyloidosis cases increasing from 16 to 25 between 2018 and 2023. Therefore, we report here the significant impact of the APC on increasing referrals for patients with ATTR, with the program facilitating diagnostic pathways for these rare conditions.</p><p><strong>In summary: </strong>Since 2022, the establishment of an amyloid screening clinic has furthered these efforts, aiming to enhance early recognition and improve clinical outcomes.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}